---
document_datetime: 2024-02-07 12:59:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/hemlibra-epar-all-authorised-presentations_en.pdf
document_name: hemlibra-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.1801677
conversion_datetime: 2025-12-30 11:04:53.668187
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/18/1271/006 | Hemlibra          | 30 mg/ml   | Solution for injection | Subcutaneous use          | vial (glass)          | 0.4 ml                    | 1 vial      |
| EU/1/18/1271/001 | Hemlibra          | 30 mg/ml   | Solution for injection | Subcutaneous use          | vial (glass)          | 1 ml                      | 1 vial      |
| EU/1/18/1271/002 | Hemlibra          | 150 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 0.4 ml                    | 1 vial      |
| EU/1/18/1271/003 | Hemlibra          | 150 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 0.7 ml                    | 1 vial      |
| EU/1/18/1271/004 | Hemlibra          | 150 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 1 ml                      | 1 vial      |
| EU/1/18/1271/005 | Hemlibra          | 150 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 2 ml                      | 1 vial      |